Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 2/20 | 0.52 |
| ▸ | ALPG | P10696 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118365 | 0.83 | ALPL (0.58) | ALPLMEN1KMT2APOLBTSHR | |
| SCHEMBL15661830 | 0.83 | ALPL (0.58) | ALPLMEN1KMT2APOLBTSHR | |
| SCHEMBL16975842 | 0.83 | POLB (0.59) | ALPLMEN1KMT2APOLBTSHR | |
| Benzene SCHEMBL29186724 | 0.80 | POLB (0.60) | ALPLMEN1KMT2APOLBTSHR | |
| SCHEMBL11882709 | 0.80 | F2 (0.50) | ALPLMEN1KMT2APOLBMAPT | |
| SCHEMBL9415779 | 0.80 | POLB (0.79) | ALPLMEN1KMT2APOLBTSHR | |
| Hydrochloric Acid SCHEMBL28173449 | 0.79 | F2 (0.49) | ALPLMEN1KMT2APOLBMAPT | |
| SCHEMBL10153780 | 0.79 | SMN1; SMN2 (0.64) | ALPLMEN1KMT2APOLBTSHR | |
| Benzoxazolinone SCHEMBL5802051 | 0.76 | OGT (0.62) | ALPLMEN1KMT2APOLBTSHR | |
| SCHEMBL26434348 | 0.76 | POLB (0.58) | ALPLMEN1KMT2APOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861566-B1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | claimed |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | claimed |
| CN-101454289-B | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicine | ESTEVE LABOR DR | 2012-07-04 | — | — | CN | claimed |
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | claimed |
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | claimed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | claimed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | claimed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | claimed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | claimed |
| EP-2079701-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-22 | — | — | EP | claimed |
| CN-101454289-A | Substituted tetrahydroisoquinoline compounds, their preparation and use in medicine | ESTEVE LABOR DR (ES) | 2009-06-10 | — | — | CN | claimed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-2007729-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-31 | — | — | EP | claimed |
| WO-2008043544-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-04-17 | — | — | WO | claimed |
| EP-1899296-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | claimed |
| WO-2006136924-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-12-28 | — | — | WO | claimed |
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| EP-1467986-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062224-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | ALPL 4420/4885MEN1 233/4885KMT2A 1496/4885 |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | CNR2, CNR1, FAAH | ALPL 4130/4885MEN1 1647/4885KMT2A 2634/4885 |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | ALPL 1505/4885MEN1 2959/4885KMT2A 1261/4885 |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | ALPL 3522/4885MEN1 4142/4885KMT2A 1366/4885 |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | ALPL 3311/4885MEN1 839/4885KMT2A 2232/4885 |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | DAPK2, DAPK1, IDH3A | ALPL 4744/4885MEN1 147/4885KMT2A 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.